Immunization, Vaccines and Biologicals

Update on the CYD-TDV Phase 3 trial in Asia

Sanofi Pasteur announced the preliminary results of a Phase 3 trial of its candidate dengue vaccine conducted in five countries in Asia.

This is the first Phase 3 trial of a dengue vaccine candidate ever completed. WHO welcomes the encouraging data on vaccine safety and efficacy. Once the detailed study results are publically available, WHO will provide an independent assessment. WHO also awaits the results of another Phase 3 study conducted with the same vaccine in five countries in Latin America.

The growing global epidemic of dengue is of mounting concern, and a safe and effective vaccine is urgently needed. WHO expects vaccines to be an integrated part of the Global dengue prevention and control strategy (2012-2020).

Advisory groups